In a decision with important implications for the evolving field of personalized medicine, a unanimous U.S. Supreme Court on Tuesday invalidated two patents on a diagnostic test used in connection with the treatment of autoimmune diseases.

Mayo Collaborative Services v. Prometheus Laboratories pitted doctors and researchers against biotechnology and pharmaceutical companies in the ongoing debate over what is patentable subject matter.